A few socks of ASX listed companies are comparatively young but potential growth companies. Two such companies are
Echo IQ Limited (ASX: EIQ)
Echo IQ Limited (ASX: EIQ) has achieved a significant milestone in its US market entry strategy with the announcement of a Miscellaneous Code (93799) for its AI-enabled EchoSolv-AS technology. This code, effective December 9, 2024, enables reimbursement on a fee-per-use basis, with rates between US$100 and US$150, notably higher than initial estimates of US$68. Reimbursement revenues will be shared between technology users and the company, with Echo IQ’s share projected at 30-60%. This development highlights a crucial step towards broader reimbursement, with further advancements expected in early CY25.
To support early adopters like Beth Israel, Echo IQ has developed comprehensive resources to assist billing departments in engaging with insurers. This progress underscores the company’s commitment to delivering measurable improvements in screening for aortic stenosis (AS) and enhancing patient outcomes, marking a path toward its first US revenues. Industry engagement remains robust, with strong interest from large US healthcare and financial organizations. Despite reporting a net loss of $5.41 million for FY24, improved from $7.86 million in FY23, Echo IQ is strategically positioned for growth. Operating revenue declined to $44,500 (FY23: $107,332), while operating expenses rose to $6.64 million, reflecting investments in AI solutions. Cash outflows from operations totaled $3.92 million, partially offset by $2.76 million raised through financing activities. Net assets fell to $6.77 million due to strategic investments. EchoSolv-AS recently secured 510(k) FDA clearance, permitting its US marketing as a decision-support tool for severe AS detection. Clinical validation includes publication with Harvard Medical School’s Beth Israel Deaconess Medical Center and presentations at the European Society of Cardiology Congress. Integration with existing echocardiography platforms is advancing, streamlining adoption by US healthcare providers.
Among growing companies to invest in, Echo IQ is also exploring heart failure diagnostics, targeting a global market exceeding 60 million patients. This initiative is supported by predictive algorithms that may unlock new customer segments. Negotiations with major US hospital groups and commercial partners are underway, leveraging FDA clearance to accelerate adoption. The company raised $7.1 million to drive its commercialization efforts, signaling a focus on executing its strategic vision. Echo IQ remains committed to transforming the early diagnosis of structural heart disease through AI innovation, solidifying its position as a leader in the field. Further updates on operational progress and partnerships are anticipated, with momentum building for CY25.
BrainChip Holdings Limited (ASX: BRN)
BrainChip Holdings Limited (ASX: BRN) announced a significant achievement on December 10, 2024, securing a US$1.8 million contract with the Air Force Research Laboratory (AFRL) under the US government’s Small Business Innovation Research (SBIR) program. This contract focuses on neuromorphic radar signaling processing, with BrainChip tasked to develop advanced algorithms and neural networks for radar systems optimized for its neuromorphic hardware. The collaboration, set to run for 12 months, will involve utilizing BrainChip’s proprietary Temporal Event Neural Network (TENNs) technology and Akida 2.0 hardware to enhance micro-Doppler signature analysis for military applications. This contract is an endorsement of BrainChip’s neuromorphic technology, which offers low-power, high-performance computing suitable for space and defense missions.
During the September 2024 quarter, BrainChip continued progressing its commercialization efforts, securing new contracts including a €190,000 deal with Frontgrade Gaisler and Airbus Defence and Space for AI projects in space applications. The company also made strides in strengthening its leadership team, appointing Steven Brightfield as Chief Marketing Officer and Dr. Jonathon Tapson as Vice President of Engineering. Additionally, BrainChip reconstituted its Scientific Advisory Board, bringing in key figures to guide its future R&D and strategic goals. The company also successfully raised A$25 million in equity, including an underwritten A$20 million placement, to support the commercialization of its Akida 2.0 and TENNs technologies.
BrainChip ended the September quarter with US$25.6 million in cash, up from US$10.9 million in the previous quarter, with net operating cash outflows of US$3.4 million. Despite experiencing long sales cycles, the company remains optimistic, bolstered by the ongoing interest from prospective customers. Operational cash inflows were modest, but the company’s strong cash reserves position it well for future growth. Furthermore, funds raised from capital activities will be used to accelerate the development and commercialization of new products, ensuring continued progress in AI-driven solutions for various industries.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.